Skip to main content
ARTL logo

Artelo Biosciences, Inc.

ARTLNASDAQHealthcareBiotechnology

$2.70Today:- (-)1Y −34.61%

As of Oct 16, 2026 close

Market cap
$825.65K
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.19$19.91
Volume (live)
-
Avg. volume (3M)
946.24K

Artelo Biosciences (ARTL) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Artelo Biosciences used $8.52M of cash in operating activities. Free cash flow was −$8.52M.

Artelo Biosciences Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Artelo Biosciences, Inc. (ARTL) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2022FY 2021FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Mar 2023Dec 2022Dec 2021Aug 2021Aug 2020Aug 2019Aug 2018Aug 2017
Operating Activities
Net Income-12.88-9.83-9.29-10.08-10.08-7.44-7.44-4.66-2.17-2.34-0.23
Depreciation & Amortization0.150.000.000.00--0.000.000.000.000.00
Deferred Income Tax0.000.000.000.00--0.000.00-1.010.000.00
Stock Based Compensation1.140.821.022.462.462.801.530.380.430.290.00
Change in Working Capital1.790.940.66-0.17-0.22-0.24-0.24-0.04-0.140.440.01
Change in Accounts Payable1.310.480.300.02-0.010.000.000.13-0.180.500.02
Change in Other Working Capital0.380.000.37-0.20-0.21-0.24-0.24-0.170.04-0.060.00
Other Operating Activities1.460.00-0.60-0.21-0.170.010.01-0.030.100.000.00
Net Cash from Operating Activities-8.52-8.35-8.21-8.01-8.01-8.00-6.14-4.35-2.79-1.61-0.22
Investing Activities
Capital Expenditures0.000.000.000.00--0.000.00-1.500.000.00
Purchases of Investments-0.25-0.48-13.69-13.22-13.22-6.10-6.100.000.000.000.00
Sales/Maturities of Investments0.198.2517.1916.1816.182.662.660.000.000.000.00
Net Cash from Investing Activities-0.067.773.512.962.96-30.10-3.440.00-1.500.000.00
Financing Activities
Debt Repayment-0.020.000.000.00--0.010.000.000.000.000.00
Common Stock Issued6.280.110.570.00-14.1214.121.988.381.390.77
Common Stock Repurchased0.000.000.000.00--0.000.000.000.000.00
Other Financing Activities0.000.000.000.00--0.01-0.010.000.000.000.04
Net Cash from Financing Activities6.870.110.570.00-54.7814.111.988.381.390.79
Summary
Effect of Forex Changes on Cash-0.02-0.010.06-0.22-0.22-0.05-0.050.080.00-0.010.00
Net Change in Cash-1.74-0.48-4.07-5.27-5.2716.604.49-2.284.09-0.240.57
Cash at Beginning of Period2.342.826.8912.1612.16-2.144.420.340.570.00
Cash at End of Period0.602.342.826.896.89-6.632.144.420.340.57
Free Cash Flow-8.52-8.35-8.21-8.01-8.01-8.00-6.14-4.35-4.29-1.61-0.22

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Artelo Biosciences Cash Flow

What is Artelo Biosciences's free cash flow?

Artelo Biosciences had negative free cash flow of $8.52M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Artelo Biosciences pay dividends or buy back shares?

Artelo Biosciences's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition